Although substantial evidence indicates that the progression of pathological changes of the neuronal cytoskeleton is crucial in determining the severity of dementia in Alzheimer's disease (AD), the exact causes and evolution of these changes, the initial site at which they begin, and the neuronal susceptibility levels for their development are poorly understood. The current clinical criteria for diagnosis of AD are focused mostly on cognitive deficits produced by dysfunction of hippocampal and high-order neocortical areas, whereas noncognitive, behavioural and psychological symptoms of dementia such as disturbances in mood, emotion, appetite, and wake-sleep cycle, confusion, agitation and depression have been less considered. The early occurrence of these symptoms suggests brainstem involvement, and more specifically of the serotonergic nuclei. In spite of the fact that the Braak and Braak staging system and National Institutes of Aging -Reagan Institute (NIA-RI) criteria do not include their evaluation, several recent reports drew attention to the possibility of selective and early involvement of raphe nuclei, particularly the dorsal raphe nucleus (DRN), in the pathogenesis of AD. Based on these findings of differential susceptibility and anatomical connectivity, a novel pathogenetic scheme of AD progression was proposed. Although the precise mechanisms of neurofibrillary degeneration still await elucidation, we speculated that cumulative oxidative damage may be the main cause of DRN alterations, as the age is the main risk factor for sporadic AD. Within such a framework, b-amyloid production is considered only as one of the factors (although a significant one in familial cases) that promotes molecular series of events underlying AD-related neuropathological changes.
Introduction
Many neurological conditions, and particularly neurodegenerative diseases, involve the selective loss of specific neuronal populations. One notable example is Alzheimer's disease (AD) in which an identifiable subpopulation of large, cortically projecting, pyramidal neurones in highorder regions of the neocortex are preferentially affected in the course of the disease [1, 2] . These neurones share a particular morphological and neurochemical phenotype characterized by their size, distribution and connectivity and their high expression of dephosphorylated epitopes of neurofilament proteins. They are affected by neurofibrillary tangles (NFTs) formation at very early stages of AD, degenerate at a faster rate than other pyramidal neurones and shrink significantly in the process [2, 3] . However, even more than 100 years after its initial clinicopathological description, no satisfactory explanation for the neuronal specificity of the degenerative process in AD is available.
The amyloid cascade hypothesis began to take shape in late 1980s when a gene on chromosome 21 that produces amyloid precursor protein (APP) was discovered [4] . In short, the APP gene contains the sequence for the b-amyloid peptide, which is concentrated in the senile plaques (SPs) used to diagnose AD (Table 1) . Some people who inherit a form of early-onset familial AD have a mutation in the APP gene that results in the overproduction of the b-amyloid. Similarly, people with Down syndrome, who invariably develop AD in middle age, have an extra copy of chromosome 21 containing the APP gene, causing them to produce excess amount of the b-amyloid protein [5] . A variety of enzymes in the brain normally process APP into soluble, seemingly harmless fragments.
However, a specific b-secretase cleaves APP in its extracellular domain and leaves a fragment (known as C99) that is secondarily cleaved by the transmembrane g-secretase complex (which includes presenilin) to cleave APP to yield the b-amyloid peptide. It is now well established that b-amyloid exists as monomers, oligomers and fibrils. It seems that b-amyloid peptide has a spontaneous tendency to form oligomers that eventually accumulate into diffuse deposits. Diffuse deposits of b-amyloid have been found in large numbers even in subjects whose intellectual status had been evaluated as normal both neuropathologically [6] and by in vivo visualization using Pittsburgh compound B positron emission tomography (PIB PET, see below) [7] . It is not known how long diffuse deposits may remain asymptomatic in the brains of cognitively intact subjects and why only certain regions of the brain are susceptible to their 'maturation' into focal deposits and neuritic ('mature') plaques (characterized by a corona of The combination of BB NFTs stage equal to or above IV and CERAD NP stage C together with CDR equal to or above 1 provides the highest sensitivity and specificity; NIA-RI criteria are more specific than CERAD, but less sensitive degenerating neurites containing tau protein paired helical filaments around an amyloid core). One hypothetical view for maturation of diffuse a-helical deposits of b-amyloid into focal deposits made of firm b-pleated sheet fibrils involves the presence of copper and zinc ions [8] .
The presence of unsoluble b-amyloid fibrils in the neuropil is thought to be one of the major mechanisms that compromises axoplasmic flow and induces neurofibrillary changes (see below).
On the other hand, it has been shown that even naturally secreted oligomers of b-amyloid may inhibit hippocampal long-term potentiation in vivo [9] . Moreover, it has recently been demonstrated that amyloid oligomers isolated from the brains of AD patients and injected into rodents are capable of disrupting N-methyl-d-aspartic acid (NMDA) receptors and impairing memory [10] . Thus, free-floating oligomers may affect synaptic function years if not decades before symptoms of AD appear. On these premises it can be further speculated that soluble amyloid oligomers interfere with neurotrophic factors released into the synaptic cleft, producing anterograde neurodegeneration during the evolution of AD. Obviously, if this concept is correct, the anti-amyloid therapies would be far more effective if started earlier, before the 'toxic' oligomers have had time to alter synaptic transmission (at the same time this would confirm that formation of b-amyloid deposits is actually a defence mechanism). However, although most current research still follows the path charted by the concept of amyloid cascade hypothesis, it seems that efforts towards an effective treatment and prevention will require some new perspectives, particularly for sporadic AD. Namely, data collected so far strongly indicate that mutations in PRESENILIN-1 (PS-1), PRESENILIN-2 (PS-2) and APP genes have more widespread effects on broader range of cellular functions compared with sporadic cases [11] . One obvious example is that the enhanced g-secretase production of b-amyloid is not a feature of sporadic AD.
Current state of knowledge
In recent years it became clearer that cerebrospinal fluid (CSF) biomarkers, particularly phosphorylated tau proteins, demonstrate a higher predictive value over algorithms comprised of clinical, neuropsychological and imaging modalities [magnetic resonance imaging (MRI), single-photon emission computed tomography (SPECT), positron emission tomography (PET)] [12] . As the use of some of those biomarkers has been improved to a level that relatively early and reliable diagnosis of AD became possible, CSF examination is becoming a part of the routine diagnostic work-up for suspected AD in both clinical and neuropathological evaluation of a patient.
Considering the therapy of AD besides the currently registered cholinomimetic agents for early (donepezil, galantamin, rivastigmine, tacrine) and noncompetitive antagonist of glutamatergic NMDA receptors (which is also an antagonist of serotonin 5-HT 3 receptors) for moderate/late AD (memantin), new drugs, mainly b-and g-secretase inhibitors, were recently being developed and are currently being tested through various phases of clinical trials in order to prevent the formation and accumulation of the b-amyloid peptide, at least in those subjects with familial early-onset AD (FAD) due to mutations in PS-1, PS-2 and APP genes [13] . However, for the vast majority of sporadic, late-onset AD subjects, the neuropathological evidence collected so far does not support the amyloid cascade hypothesis, which is considered too narrow to explain all of the molecular mechanisms that lead to the characteristic accumulation of the neuropathological hallmarks of the disease [14] . It is therefore not surprising that all therapeutic efforts aimed at lowering b-amyloid production and aggregation (including passive and active immunizations) failed to show clinical improvement in AD patients [14] .
Unanswered questions
The original amyloid hypothesis contains a conspicuous inconsistency that the number of SPs found in elderly brains does not correlate with dementia. On the contrary, substantial evidence has been gathered that the progression of pathological changes of the neuronal cytoskeleton is crucial in determining the severity of dementia in AD [12, [15] [16] [17] . This fact is strengthened by the numerous reports showing that mutations of TAU gene cause hereditary tauopathies with dementia, most notably frontotemporal lobar degeneration (FTLD), in absence of b-amyloid accumulation [18] [19] [20] [21] . Although there has been some experimental support for a possible direct causal relationship between the fibrillar b-amyloid [22] or more recently the intraneuronal prefibrillar b-amyloid1-40, b-amyloid1-42 and b-amyloid oligomers [23] [24] [25] and the acute hyperphosphorylation of tau proteins (that is presumed to be continued into full-blown neurofibrillary degeneration) in several cell cultures and transgenic animal models, the exact causes and evolution of human AD-related cytosk-eletal changes, their starting point, mechanisms of spreading and the precise causal relationships between plaques and tangles all await elucidation. These problems are also related to the question of AD as a single disease. From the genetic, clinical and neuropathological point of view, AD is a multifactorial and very heterogeneous disorder [14, 26] . Nevertheless, the existence of a common pathophysiological mechanism together with spreading of neurofibrillary degeneration in a more or less orderly fashion in most patients would justify keeping AD as a single disease as originally believed by Alzheimer himself.
Why only certain types of neurones are preferentially affected in the brain, principally the cerebral cortex, in a layer-and region-specific manner remains unclear. There is ample evidence that in the neocortex, large pyramidal neurones in the deep part of layer III (layer IIIc) and the superficial part of layer V (layer Va), characterized by high somatodendritic levels of nonphosphorylated neurofilament protein, are selectively vulnerable in the course of AD [2] . Stereological analyses showed that their numbers decrease dramatically in cases with definite dementia compared with other neurones not characterized by this phenotype, to a nearly complete loss (>90%) in end-stage AD [3] . These neurones shrink considerably (by about 50% of their initial perikaryal volume) during NFT formation, the ones larger than 6 000 mm 3 being preferentially affected. Stereological data show that these neurones are lost at a faster rate in the course of AD than other and smaller pyramidal neurones, which, being less prone to NFT formation, may die through other mechanisms in AD, such as oxidative stress, abortive apoptosis (abortosis) and excitotoxic mechanisms [27] [28] [29] [30] . Considering that these neurofilament-enriched neurones represent only about 30% of the total number of pyramidal neurones in dorsolateral prefrontal cortex [3] , their preferential involvement suggests that highly specific cortical pathways are at higher risk for degeneration in AD and that the neurones providing such projections represent important cortical targets for early neuroprotective interventions in AD. In addition to the known alterations of myelin sheath integrity observed during normal brain ageing in primates [31] , the progressive loss of white matter that is observed over the course of AD [32] ultimately leads to a syndrome of neocortical disconnection. The periventricular white matter changes (leukoaraiosis) that are commonly seen in AD and are associated with low cognitive performance seem to result from a combination of ischaemia and a failure of CSF to be drained along perivascular pathways that are blocked by the deposition of b-amyloid (cerebral amyloid angiopathy, CAA) and fibrosis in the walls of arteriolosclerotic arteries in the white matter [33] . As a consequence, CSF infuses into periventricular white matter thus increasing signal in T2-weighted MRI images [34, 35] .
Neuropathological diagnostic criteria for AD

National Institutes of Aging (NIA) (Khachaturian) criteria
The first neuropathological diagnostic criteria for AD were based on quantification of minimal SPs cortical densities as a function of age [36] (Table 1 ). They were not broadly accepted because SP formation was later shown to be partly a benign age-related phenomenon (making criteria less sensitive) [15] . Moreover, the cortical regions for quantification as well as the role of the clinical history were not well defined (making criteria less specific and noncomparable) and neurofibrillary changes [NFTs, neuritic plaques (NPs) and neuropil threads] were not considered. Therefore, another set of standardized criteria known as CERAD (Consortium to Establish a Registry for Alzheimer's disease) was proposed [37] .
CERAD criteria
CERAD semiquantitative criteria were determined as a function of neocortical NPs development in the superior temporal gyrus, prefrontal cortex and lower parietal lobule using modified Bielschowsky or thioflavin S staining in three age groups (less than 50, 50-75 and over 75 years) [37] (Table 1) . Based on the combination of clinical information and NPs score, three levels of diagnostic certainty were assessed (definite, probable or possible AD). Besides the fact that the hippocampal formation was again absent from criteria (despite its well-known characteristic and crucial involvement in the initial stages of typical AD), the major weakness of CERAD criteria was that they relied chiefly upon the overproduction and accumulation of b-amyloid, and did not consider neocortical NFTs. Unlike SPs, except in low quantities in the entorhinal cortex [38, 39] , neocortical NFTs are not present in normal ageing and were later confirmed (in contrast to SPs) to correlate strongly with dementia severity [12, 15] . However, although clinicopathological correlations showed the best correlation of dementia with the quantity of NFTs, the pattern of synapse and neurone loss in AD Does Alzheimer's disease begin in the brainstem? 535 does not necessarily match the pattern of NFTs formation [29, 38, 40] .
Braak and Braak staging system
In the meantime, the Braak and Braak staging system (BBSS) became widely accepted for scoring the neurofibrillary changes in AD [41] . The BBSS classifies the progression of AD neurofibrillary degeneration in six stages, spreading from the transentorhinal region (stage I) to the hippocampal formation (stage II), the temporal, frontal and parietal neocortex (stages III and IV), and finally to unimodal and primary sensory and motor areas of the neocortex (stages V and VI). Illustration of early neurofibrillary changes in entorhinal and temporal cortex and hippocampal formation in two patients who fulfilled clinical criteria for AD is given in Figure 1 . In short, our observations indicate that changes in limbic tau pathology spread in a highly ordered manner from layer II Figure 1 . Illustration of neurofibrillary changes, which in Alzheimer's disease (AD) spread in an anterograde fashion through identified neuronal circuits due to yet unknown cause(s). All figures were obtained using the mouse monoclonal antibody AT8 (Innogenetics, Temse, Belgium) used at a 1:200 dilution in indirect immunocytochemistry. It should be stressed that AT8 reacts with tau only when multiple sites around Ser202, including Ser199, Ser202 and Thr205, are phosphorylated. Single phosphorylation of any of these residues is not enough for AT8 reactivity. Thus, AT8-immunoreactivity is useful in detecting phosphorylation of Ser202/Ser202/Thr205 for proline-directed kinases. entorhinal neurones to cells located in deeper entorhinal layers, hippocampal formation and temporal isocortex. For example, the epitope Ser199/Ser202/Thr205 (as revealed by monoclonal antibody AT8) has been always found phosphorylated before the Ser396/Ser404 epitope (monoclonal antibody AD2) [42, 43] , whereas cleaved tau (detected by antibody MN423) could not be found in layers free of phosphorylated tau at these sites [43] .
National Institutes of Aging -Reagan Institute (NIA-RI) criteria
In an attempt to reconciliate the amyloid hypothesis with the major role of NFT in clinicopathological correlations, in 1997, the more rigorous National Institute on AgingReagan Institute (NIA-RI) consensus recommendations for the post mortem diagnosis of AD were issued [44] ( Table 1) . NIA-RI criteria use CERAD protocols for tissue processing, as well as a semiquantitative assessment of AD lesions that must be made in several neocortical areas, hippocampus, substantia nigra and locus coeruleus, while also taking into account the BBSS for neurofibrillary changes. In contrast to CERAD criteria, which incorporate clinical data to provide a neuropathological diagnosis, NIA-RI criteria primarily aim to define the probability that clinical dementia was really due to AD-related lesions. Because NIA-RI criteria take into account the apparent number of neocortical NFT, in comparison with CERAD they are more specific but less sensitive, as many AD patients have low numbers of neocortical NFT [45] . As such, definitive neuropathological criteria for AD are still lacking.
The role of reactive processes in the pathogenesis of AD
Generally, the AD pathological changes can be broadly divided into three categories: lesions related to accumulation ('positive lesions'), lesions due to losses ('negative lesions') and those related to the reactive processes such as inflammation and plasticity ('reactive lesions') [46] . The losses of synapses and neurones are probably most directly related to the neurological deficits observed in AD patients. However, as they are difficult to estimate and evaluate neuropathologically, so far only the 'positive lesions' that are easy to detect constituted the basis for the postmortal diagnostic criteria. On the other hand, the reactive processes are often thought to appear late during the course of the disease and were therefore not considered adequate to be included in the neuropathological diagnostic criteria for AD.
Neuroinflammation as a possible link between amyloid deposition and neurofibrillary degeneration
It has been recently suggested that microglial activation may occur very early during the course of AD and that neuroinflammation may represent the possible link between amyloid deposition and neurofibrillary degeneration. A recent study investigating plasma biomarkers that could predict conversion from mild cognitive impairment (MCI) to clinical AD identified raised levels of several cytokines and interleukins (ILs) associated with inflammation [tumour necrosis factor a (TNFa), IL-3, IL-1a and IL-11], which are secreted by microglial cells [47] . In turn these pro-inflammatory factors may change the substrate specificity of kinases/phosphatases leading to tau phosphorylation at pathological sites [48] . Albeit indirect, further evidence to support a possible link between inflammation and AD comes from increased risk of dementia in people who suffered a serious head injury [49, 50] , patients with cerebral ischaemia [51] and subjects with type 2 diabetes mellitus and insulin resistance [52, 53] . All of these three conditions are associated with increased production of pro-inflammatory molecules and a higher propensity to develop AD or to exacerbate AD symptoms.
The key role of tau protein in development and progression of cytoskeletal neurofibrillary changes and reactivation of foetal plasticity in AD
The key role of microtubule (MT)-associated protein tau in AD and related neurodegenerative disorders stems from its roles in neural development and cytoskeleton maintenance. Under normal circumstances, by binding to MTs, tau regulates their stability and dynamics [54] . The human protein tau is encoded by a single gene located on the long arm of chromosome 17. Tau promoter activity increases significantly during neurite initiation and outgrowth. The human tau primary transcript contains 13 exons of which exons 2, 3 and 10 alternatively spliced and give rise a family of six isoforms [55] . As in aged and cognitively impaired animals the neurofibrillary degeneration due to abnormal phosphorylation of tau protein is Does Alzheimer's disease begin in the brainstem? 537 scarcely found, the unique expression pattern of tau isoforms in the human central nervous system has been suggested as a possible trade-off between increased cognitive capabilities and decreased resistance to neurodegenerative disorders with tauopathy, especially AD and FTLD [56] . Except for AD and adult cases of Down syndrome that are characterized by both neurofibrillary pathology due to abnormally phosphorylated tau and b-amyloid plaques, all other tauopathies, such as FTLD due to tau mutations, argyrophilic grain disease, corticobasal degeneration and progressive supranuclear palsy (PSP), boxer's dementia, Guam parkinsonism-dementia complex, pallido-pontonigral degeneration, and others [57] , are characterized by neurofibrillary pathology in the absence of b-amyloid plaques [21, 58] . In all of these tauopathies, the tau mutation is sufficiently potent to induce tau aggregation and NFTs in absence of b-amyloid, and is associated with cognitive deterioration and dementia (later appearance of b-amyloid may accelerate this process significantly) [59] . Furthermore, in many sporadic cases of AD, particularly in subjects over 80 years of age, the so-called 'tangle only' AD may be the predominant form [60] comprising about 4% of all AD cases [61] .
The molecular species and biological activity of tau are developmentally controlled mainly by phosphorylation of its six isoforms [55, 62, 63] . The majority of the phosphorylation sites are clustered in the flanking regions of the MT-binding domain [55] . In turn, tau proteins change physical characteristics of MTs such as rigidity, length, stability and integrative capacity with other organelles. While normal tau promotes and stabilizes MTs, the nonfibrillized, abnormally hyperphosphorylated tau disrupts MTs, sequesters normal tau, decreases its turnover (due to increased resistance to degradation by calcium-activated neutral proteases, calpains, and ubiquitin-proteosome pathway), misfolds and finally promotes self-assembly into straight or paired helical filaments (PHFs), thus impairing axoplasmic flow and leading to slow degeneration [14, 64] . In the foetal human brain, there is only one isoform referred to as foetal tau [65] , which has three domains (3R) for binding to MTs. It is thought that the absence of expression of the fourth MT-binding domain during foetal development prevents MTs bundling [14] and allows for the cytoskeletal plasticity required for immature growing neurones [66, 67] . Adult tau isoforms have four MT-binding domains (4R tau) and are about 40-fold more efficient at promoting MT assembly [68] [69] [70] . The 4R tau protein and particularly the mutated tau protein studied in the most common missense mutations causing frontotemporal dementia with parkinsonism (G272V, P301L, V337M and R406W) are more easily abnormally phosphorylated and more readily selfaggregate into filaments [67] , which may explain an earlier onset and greater severity of the disease in the inherited FTDP-17 cases. As in situ hybridization analysis showed no significant change in the expression of tau mRNA in AD brain [71] , the increase in tau level observed in AD brains is probably due to a decrease in its turnover caused by phosphorylation. Out of 80 putative Ser or Thr phosphorylation sites on the longest brain tau isoform, so far 45 of them have been characterized by monoclonal antibodies, mass spectrometry and sequencing [14, 55] . Most of the phosphorylation sites are on Ser-Pro and ThrPro motives, but a number of sites on other residues have also been reported [72] . Different states of tau phosphorylation result from the activity of many different specific kinases, of which the most important are probably proline-directed (that is, acting on serine/threonine followed by proline) kinases glycogen synthase kinase 3b (GSK-3b), mitogen-activated protein kinases ERK 1, ERK2, p70S6 and stress-activated kinases JNK and p38, cyclin-dependent protein kinase-5 (cdk5), and Dyrk1A [14, 73] because they have the ability to phosphorylate tau at a large number of sites. Although nonproline-directed protein kinases (such as MT affinity-regulating kinase, calcium/calmodulin kinase II, protein kinase A, and others) have been shown to phosphorylate tau at only a very limited number of sites, their importance may be underestimated because phosphorylation of tau by these enzymes significantly increases the phosphorylation of tau by GSK-3b and cdk5 [14] . The decreased activity of at least four different protein phosphatases (PP-1, PP-2A, PP-2B and PP-2C) can also lead to tau hyperphosphorylation in AD [55, 74] . Inhibitors of the main phosphatase PP-2A, such as I 1 PP-2A and I2
PP-2A
, thus also represent potential therapeutic targets for halting the progression of neurofibrillary degeneration in both AD and normal ageing [14] .
Hypothesis of reactivation of foetal plasticity in AD
Phosphorylation of tau proteins is high in the foetal period during axonal elongation (Figure 2 ), and decreases with advancing age due to activation of phosphatases [62, 63] . However, after about 30 years of age, yet unknown single or more probably multiple factors such as genetic dysfunction that may include both mutational (APP, PS-1 and PS-2, TAU genes) and diverse susceptibility loci (e.g. APOE, a2M, aACT, LRP1, IL1a, TNFa, ACE, BACE, BCHE, CST3, MTHFR, GSK3b, NOS3, mitochondrial CO1 and CO2), as well as environmental influences (e.g. head trauma), seem to converge to a single common pathogenic pathway, which causes the phosphorylation of tau to increase again (perhaps together with increased cleavage of tau, which may make tau an even more favourable substrate for abnormal hyperphosphorylation), causing tau polymerization and formation of straight and paired helical filaments that form NFTs, dystrophic neurites and neuropil threads [14] . Impaired brain glucose metabolism has also been shown to facilitate abnormal tau hyperphosphorylation in cultured cells and in mouse models of sporadic AD by at least two different mechanisms, abnormal glycosylation of tau [75] and impaired insulin receptor signalling cascade [76] .
The genetic influences on lifespan were shown to be minimal prior to age 60 but increase thereafter [77] . Clearly, the ageing process itself contributes to AD. However, AD should not be regarded as 'accelerated ageing' considering that many people live to extreme age with only minor loss of mental abilities. The autopsy performed on the world's oldest woman, who lived to be 115 years old, reported that her brain was virtually free of neuropathological signs of AD [78] . Besides the cumulative oxidative damage by reactive oxygen species (ROS) [79] , which can be provoked by b-amyloid or its fragments [80] , some of the hypotheses on putative initial triggers that may activate and speed up AD-related pathological processes include proposal of neuronal failure due to plasticity burden [81] , the potentially detrimental effect of Herpes simplex virus through either the activation of Tolllike receptor pathways in astrocytes and microglia or a change in the phosphorylation state of tau [82] [83] [84] , brain ischaemia and ischaemic blood-brain barrier [85] , and genetically programmed adaptive metabolic reduction [86] . One of the most plausible concepts that links plaques and tangles in a causative way stems from the idea that the key pathogenetic event and the main mechanism that induces physical damage to axons thus compromising axoplasmic flow is the fibrillogenesis of diffuse b-amyloid deposits (see above) [87] . Neuronal response to this kind of injury results in axonal sprouting [88] , upregulation of tau mobilization and its excessive phosphorylation. In order to find the proper path to its targets and form synapses, in these regenerative processes of sprouting and pruning, axonal growth cones and their core MTs need to be less stable [88] . In other words, to induce this level of MTs plasticity, tau proteins need to be in a more phoshorylated state. As we found that the same epitope revealed by the antibody AT8 (Ser202/Ser202/Thr205) is phosphorylated both in growing foetal axons and in degenerating axons of AD brains (compare Figures 1 and 2) , and taking into account the fact that AT8-immunoreactivity permits evaluation of neuronal changes well before the actual formation of NFTs and neuropil threads [30, 89] , we speculate neurofibrillary degeneration at least in its earliest stages may include pathological activation of some foetal proline-directed protein kinases, such as one of 100 kDa weight that phosphorylates Ser262 of tau protein [90] . In turn, such kinases may reactivate foetal plasticity mechanisms through phoshorylation of tau protein, this time however in degenerating axons of AD brains, further contributing to the development and progression of AD-related pathological changes.
Clinical criteria for AD and problems of antemortem diagnosis
The introduction of potential new treatments and drugmodifying therapies such as g-and b-secretase inhibitors, blockers/inhibitors of b-amyloid aggregation and fibrillization, MT stabilizers, muscarinic agonists and others that are supposed to have the best effect if introduced early, as well as potentially better symptom-management therapies (5-HT1a agonists and antagonists, 5-HT4 agonists, mitochondrial permeability modulators, calcium channel blockers), increased awareness about AD in the population and has facilitated patients and their families to seek medical advice earlier during the course of the disease [91] . Therefore, in recent years, the preclinical phase of AD with mild memory impairment, but without overt dementia, has increasingly attracted attention.
According to all clinical criteria recommended so far, AD cannot be diagnosed until dementia is present. Although the NINCDS-ADRDA (National Institute of Neurological and Communicative Disorders and StrokeAlzheimer's Disease and Related Disorders Association) criteria [92] have a relatively high accuracy rate (around 80-90%) [93, 94] , these percentages come from specialized expert research academic centres and are based on patients in later stages of the disease who were followed longitudinally for several years before autopsy. In clinical settings, there is no clinical method to determine which patients with MCI will progress to dementia, except for a very long clinical follow-up.
Mild cognitive impairment is an aetiologically heterogeneous potential precursor stage of AD, defined by cognitive impairment, that can be shown by objective neuropsychological measures adjusted for age and education. About 40-60% of amnestic MCI patients develop AD during the first 5 years [95] , whereas the remainder of MCI patients have a less progressive form of memory impairment [95, 96] . It should be kept in mind that other types of dementia, such as dementia with Lewy bodies, vascular dementia and argyrophilic grain disease (Braak's dementia), may also be preceded by MCI [96, 97] . The amnestic subtype of MCI (that is, memory complaint with objective memory impairment, but with preservation of general cognitive functioning without or with minimum impairment of activities of daily living) mostly represents prodromal AD [98] , which is confirmed neuropathologically [99] .
The major pitfall when studying CSF biomarkers to predict AD in MCI cohorts is the fact that conversion from MCI to AD is only about 12-15% per year (in contrast, only 1-2% of healthy older populations convert to AD per year) [95] .Therefore, only an extensive follow-up time (>5 years) of patients with stable MCI might further increase the specificity of CSF biomarkers [12] . On the other hand, neither the clinical nor the pathological aspects of AD evolve in a linear manner, but the predictable sequence of AD pathology allows for stage-based correlations with cognitive and behavioural symptomatology [100] . Besides CSF biomarkers, future neuropathological criteria and recommendations should therefore include more sensitive and specific immunohistochemical and immunocytochemical subgrouping [101] and neuropathological grading of AD.
Another crucial problem of antemortem diagnosis is that the reliability of both clinical and neuroimaging methods is a function of disease severity, and therefore, there is a risk of increasing overlap with non-AD pathology, psychiatric illnesses and healthy ageing [ICD-10 (International statistical Classification of Diseases and related health problems, 10th edition), DSM-IV-TR (Diagnostic and Statistic Manual of mental disorders, IV. Totally Revised edition), NINCDS-ADRDA] [92, 102, 103] , particularly in presence of comorbidities and cases of atypical AD syndromes, such as anterior (frontotemporal) and posterior (parietotemporo-occipital) variants of AD, focal, lobar or gyral progressive degenerative syndromes [104] . Moreover, the clinical spectrum of symptoms of these conditions more closely corresponds to the functional anatomy of the affected brain areas than to the underlying pathology.
The current clinical criteria for diagnosis of dementia in AD are focused mostly on cognitive deficits produced by dysfunction of hippocampal and high-order neocortical areas [92, 102, 103] . In other words, during the neuropsychological part of the diagnostic procedure, clinicians are looking for impairment of memory for recent events (Braak stages I and II), impaired recall, delayed word recall and word finding difficulties, disorientation in time and space, and impaired concentration and comprehension (Braak stages III and IV), and disturbances in perceptual and motor skills (Braak stages V and VI) [41] . These neuropsychological findings are scored as number of points that, in the most commonly used Mini-Mental State Examination (MMSE), ranges from 0 to 30 points, where 30 reflects normal mental status across many cognitive domains [105] . Although many other tests for neuropsychological screening for AD are available, they are not used as much as MMSE, which has been criticized along several lines, including sensitivity to educational level, poor sensitivity and specificity, and poor negative predictive value (NPV) and positive predictive value (PPV), especially in early-stage disease [106] (see below).
Imaging modalities to diagnose MCI or early dementia in AD are tightly bound to the measurement of the structural and functional changes in the cerebral cortex, but not other, subcortical structures (see below why authors think this should be changed). Annual rates of cortical atrophy were found to be significantly different in normal ageing (0.2-0.5%) and AD (2-3%) [107] , particularly in the entorhinal cortex and hippocampus, as revealed by structural MRI volumetric measurement [108] [109] [110] [111] [112] . An even earlier characteristic sign of incipient AD is temporoparietal hypometabolism, as assessed by [ 18 F]fluorodeoxyglucose (FDG) PET [113] [114] [115] . Recent neuroradiological advances now also allow the measurement of alterations in the white matter integrity in patients with MCI and AD using diffusion tensor imaging (DTI) [116] , diffusion tensor tractography (DTT) [117] and the in vivo investigation of amyloid pathology, visualized by PIB PET [118, 119] [123] .
Clinicopathological correlations of behavioural symptoms and pathology of raphe nuclei
Behavioural and psychological symptoms in AD
Interestingly, in a study of 1070 nondemented individuals, those who had depressed mood at baseline were found to have an increased relative risk of dementia of 2.94, even after adjustments made for age, gender, educational level and language [127] , while in a longitudinal study of 235 patients with early probable AD only 8.5% were free of noncognitive, so-called behavioural and psychological symptoms of dementia (BPSD), such as disturbances in mood, emotion, appetite and wake-sleep cycle, 'sundowning', confusion, agitation, depression and others, during the first 3 years of follow up [128] . A retrospective review of 100 autopsy-confirmed AD cases found that, on average, depression, mood change, social withdrawal and other BPSD were documented more than 2 years before the diagnosis of AD was made (the earliest noncognitive symptom appeared, on average, 33 months before diagnosis) [129] . The early occurrence of BPSD is suggestive of early brainstem involvement and more specifically of serotonergic nuclei. However, although many published investigations initially reported early involvement of the brainstem nuclei by neurofibrillary degeneration during the course of AD (particularly the raphe nuclei -see Table 2 ), due to the fact that BBSS did not include raphe nuclei in post mortem investigation of AD-related pathology (BBSS criteria were later incorporated into NIA-RI criteria for neuropathological diagnosis of AD), their pathology in AD has not been systematically studied. Because age is the main risk factor for sporadic AD, for us it is logical to assume that a cumulative oxidative damage by ROS, particularly of mitochondrial DNA [130] and RNA (RNA seems to be more susceptible to oxidative insults than DNA as RNA is largely single-stranded, its bases are not protected by hydrogen bonding and specific proteins and it locates in the vicinity of mitochondria, the Does Alzheimer's disease begin in the brainstem? 541 In comparison with controls, a large (70-80%) decrease in the number of PH8+ neurones in DRN and MRN of the AD+ subgroup (patients with significant AD-related pathology in RN) was found. In subgroup of AD-patients (those without pathology in RN), the reduction of PH8+ neurones was found only in DRN, but this change was not as dramatic as the 'pure AD', i.e. AD+ group Authors concluded that RN are damaged only in certain cases of AD, indicating that, despite patient similarities in both clinical presentation and cortical neuropathology, the disease process is not homogeneous; the consistent and specific pathology of RN found in AD+ cases and the absence of such pathology inADcases suggested that pathology in RN is not essential and, therefore, causal for dementia: patients with earlier-onset dementia had milder pathology in RN compared with later-onset patients of AD and control subjects using thioflavin S-stained sections and immunocytochemistry using 10D5, ALZ-50 and AT8 antibodies 32 26 (13 from normal subjects and 13 non-AD patients) In 72% of AD cases there were only SPs, while both SPs and NFTs were found in 9%. These changes were absent in all 26 control brains (Parvizi et al., 2000 [152] ); different monoaminergic, cholinergic and other nuclei of the brainstem were found affected to contain SPs and NFTs with varying degrees of severity, whereas no changes were seen in the brainstems of controls (Parvizi et al., 2001 [153] ) Authors concluded that PAG is selectively involved in AD; furthermore, the type and density of pathological changes correlated with the duration of dementia (Parvizi et al., 2001 [153] ); authors concluded that the finding of severe pathological changes in some brainstem nuclei raises the possibility that the dysfunction of these nuclei may contribute to cognitive defects and increased rates of morbidity and mortality in AD patients Rüb et al., 2000 [160] The goal of the study was to analyse AD-related cytoskeletal pathology in the raphe nuclei using modified silver-iodide-Gallyas staining and the AT8 antibody 27
Examination of serial sections from the brainstems of 27 post mortem cases with BB I-VI of cortical cytoskeletal lesions showed that DRN manifests the cytoskeletal lesions early on (i.e. in cortical stages I-II), the central and linear RN do so in cortical stages III-IV while the caudal raphe nuclei only in cortical stages V-VI Authors concluded that the developing damage within the nuclei of the raphe system correlates with the BB I-VI; as the source of the ascending serotoninergic system, the involvement of the oral raphe nuclei may be partially responsible for the early manifestations of the noncognitive and emotional deficiencies in AD The possible role and the significance of the early DRN involvement during AD
The human raphe nuclei consist of the rostral subdivision that gives rise to the ascending projections and caudal subdivision (nuclei raphe magnus, pallidus and obscurus) that projects into the brainstem and spinal cord. The rostral subdivision comprises the centromedian part (including the annular, linear and central raphe nuclei) and the dorsal part. The dorsal part, also known as the DRN, contains the largest aggregates of serotonergic neurones (about 80%) and is divided into the interfascicular, supratrochlear and caudal subnuclei [132, 133] . Before the introduction of BBSS many investigators reported AD-related pathology and cell loss in the raphe brain stem nuclei (in addition to those in the basal nucleus of Meynert and entorhinal cortex) during the early course of AD [134] [135] [136] [137] [138] [139] [140] [141] [142] [143] [144] [145] (see Table 2 ). However, most of them used biased methodology of estimation of nerve cell loss and frequency of tangles from densities assessed, while sampling was performed usually only at the level of trochlear nucleus, thus preventing firm conclusions to be made (see Table 2 ). In spite of the fact that after the introduction of BBSS the raphe brainstem nuclei were not in the focus of investigation, several reports, some of which used unbiased methodology for quantification, again drew attention to the possibility of their selective and early involvement, particularly the DRN, in the pathogenesis of AD [146] [147] [148] [149] [150] [151] [152] [153] [154] [155] [156] [157] [158] [159] (see Table 2 ).
Braak and colleagues later confirmed very early AD-related cytoskeletal changes in the DRN in 27 AD cases [160] (see Table 2 ). They claimed that in accordance with the cross-sectional data available to them, the ascending system source, the rostral raphe group, is affected as early as in stage I -some 30 years prior to dysmnesia -by the AD-related cytoskeletal lesions [160] .
Furthermore, it was recently reported that the DRN may actually display the earliest AD-related cytoskeletal pathology [159] (see Table 2 ). In this clinicopathological series of 118 cases, out of which 38 were categorized as Braak stage 0 (at least four sections at different levels of transentorhinal cortex were free of neurofibrillary changes, based on immunonegativity for monoclonal antibodies PHF-1 and AT8), and 80 as Braak stage ՆI (rare neurofibrillary changes in the transentorhinal cortex are considered as Braak stage I), more than 20% of Braak stage 0 and all of Braak stage ՆI cases had substantial neurofibrillary changes in the DRN. An illustration of early neurofibrillary changes of the DRN is given in Figure 3 . Therefore, the putative staging scheme updated with the DRN (and considering the DRN as the first brain structure affected by neurofibrillary pathology and the 'earliest source' of transneuronal degeneration), the crude scheme of differential susceptibility levels for neurofibrillary degeneration should be as follows: DRN → entorhinal cortex → hippocampal formation → amygdala → orbitofrontal and prefrontal cortex → posterior association cortical regions → primary sensory and motor cortical areas (from highest to lowest susceptibility). However, because the raphe nuclei dysfunction due to neurofibrillary changes is not included in the BBSS, its possible behavioural correlates are not yet considered as a poten- tial early characteristic clinical feature of AD. As a matter of fact, studies of the brainstem in AD generally do not pay much attention to the connectivity of the affected nuclei and related functional consequences. In a similar fashion, the molecular characteristics of the dorsal raphe alterations are not yet determined (see below), and cannot be used for diagnostic purposes.
Summary and future prospects
In summary, research studies conducted so far indicate that AD in familial cases due to known mutations in APP, PS-1 and PS-2 genes is probably caused by a pathological cascade of events in which formation of b-amyloid oligomers lies upstream of neurofibrillary degeneration. Neuropathologically, some of the familiar AD forms are indeed of the 'plaque only type'. As the 'toxic' b-amyloid oligomers are first being accumulated as diffuse deposits in the neuropil and later as SPs, this AD pathology is, however, an end-stage effect rather than cause or at least partially a response to initial insults, thus representing an adaptive, protective reaction [161, 162] . Despite intensive efforts to find the mechanistic missing link between plaques and tangles, the steps that connect b-amyloid and its potentially toxic oligomers to cytoskeletal tau pathology still remained largely undefined. On the other hand, in many or even most sporadic cases neurofibrillary degeneration can be caused in the absence of amyloid pathology. Thus a more coherent scheme in these cases can be based on the centrality of the cytoskeletal abnormalities [18, 163] . According to this view, the hyperphosphorylation of tau protein aids in both the development and progression of AD, while regional differences in compartmentalization and metabolism of tau protein possibly represent a molecular basis for individually and regionally different neuronal vulnerability in AD [164] . As it has been documented that hyperphosphorylated tau, but not PHFs, inhibits regeneration of MT network in cultured cells, the formation of PHF may be considered as a self-defence reaction (similarly to the formation of SPs) by the affected neurones [165] . The relationship between the quantity and distribution of NFTs, the loss of neurones and dementia, is not a linear one [29] . This could partially be attributed to the fact that due to the redundancy of nervous elements and compensatory structural, physiological and biochemical processes, a loss of neurones is to a certain limit tolerated without any functional consequences [18] . An important source of discrepancy among studies arises from the fact that most AD studies have focused on elderly people without considering the possibility of a gradual neuronal loss over adult life prior to the occurrence of AD-related changes. As long as elderly patients do not suffer from AD, they appear neuropathologically quite comparable as a group [38, 166] . It is therefore not surprising that significant neurone loss due solely to ageing cannot be revealed without younger adult cases included in the regressions [167] . On the other hand, when neuronal loss attributable to ageing is superimposed to an unbiased estimate of the number of NFTs in AD, regions like the entorhinal cortex and hippocampal formation may display neuronal losses larger than that accounted for by NFT counts alone [18, 29, [167] [168] [169] . It can be assumed that the pattern of neurone loss does not necessarily match the pattern of NFT formation due to mechanisms other than neurofibrillary degeneration [18, 29, 38, 39] .
Based on CSF levels of proteins associated with SPs and NFTs, that is, b-amyloid, total tau and ubiquitin, five different subgroups of AD have already been proposed [170] . As there is a tendency for phosphorylated tau proteins to behave differently in the different primary dementing disorders, the phospho-tau proteins in CSF come closest to fulfilling criteria of biological markers of AD [12] . It is therefore likely that additional subgroups of AD may be identified from phosphorylation patterns of CSF tau. This would help preclinical identification of specific signalling pathways involved selectively in different subgroups of AD patients and also facilitate the development of more specific therapeutic drugs.
In the context of early involvement of the raphe nuclei in AD degenerative process it would for instance be relevant to assess whether 5-HIAA (5-hydroxyindoleacetic acid), the main metabolite of serotonin in CSF, is decreased in patients with BPSD typical for very early AD and whether therefore it could be used as an early biological marker. Perhaps of equal importance would be to test for the functional correlation of genes related to serotonergic transmission that might be altered during the early course of AD by genome and transcriptome microarray analysis of blood and post mortem brain samples. A compensatory mechanism illustrated by an up-regulation of serotonergic metabolism has been shown at the stage of amnestic MCI in contrast with a dramatic decrease at later stages of AD [171] . This difference of hippocampal serotonergic receptor labelling allows distinguishing of patients with amnestic MCI from those with mild AD. Exploring 5-HT1a Does Alzheimer's disease begin in the brainstem? 547 receptors with 2′-methoxyphenyl-(N-2′-pyridinyl)-p-( 18 )F-fluoro-benzamidoethylpiperazine PET may therefore be useful for better understanding of pathophysiological changes at early stages of AD [171] .
The serotonergic neurones in the DRN can also be easily visualized and quantified by immunohistochemistry using monoclonal antibody PH8 raised against phenylalanine hydroxylase, which cross-reacts with tryptophan hydroxylase, the serotonin synthesis enzyme [148] . Expanding our understanding of the raphe nuclei, particularly the DRN involvement in the early stages of AD to functional concepts beyond neuropathological descriptions, will likely have a strong impact on our understanding, detection and tracking of AD progression, and on the development of new therapeutic strategies.
